Member Info for Newuncle

Tricky,

I think it is. As a PC survivor following surgery a few years back, I still have 6 monthly blood tests for PSA at my GP. Simply needle in the vein and fill one of those tubes which gets sent to the lab by the GP for testing and then results back in a few days. Obviously the difference with OBDs lab test is the level of detection it offers, simples.

The EpiSwitch PSE is a blood screening test for prostate cancer administered alongside or following a standard PSA test to boost accuracy significantly. EpiSwitch PSE is a routine blood test

CTSFO,

Well said there. For the less medically aware of us, could you add any more details please as I think it's very important information.

TIA

Hi Dug,

I agree with so much going on I feel the BoD have a stack of updates ready to hit the presses any day.

We are currently becalmed like a sailboat waiting for the wind to fill our sails. This is always the hardest part of investing rather than trading and keeping patient and not being tempted away by shiny new things that others are pushing or being spooked by daily market girations.

If sales are progressing as most of us think they should be wouldn't the company have issue a trading update to confirm?

I say this considering previous declared revenues v what has and should be happening re USA sales?

Is what it is, c'est la vie

Groundhog day

Shhhhh...we could be about to flip......

OK well I think we have covered all the positives here now. Maybe we should at least discuss the perceived "negatives" holding this back?

1 Mcap is way over previous earnings

2 Price has risen too fast and beyond fair value?

3 OBD cannot scale to meet demand in the USA

4 America First policy could limit sales

5 CEO sold £50k of shares

Any more you would like to add while we wait for the market to catch up

Only on AIM could find a company with proven ground breaking technology and approval by the medical insurance industry in the USA being manipulated this way.

Most AIM companies crack the UK market and then think about expansion into the USA as a longer term goal.

OBD have achieved what others could only dream of and yet AIM being full of traders and with MMs who play every trick in the book treat it like some high risk and totally speculative miner in Africa.

I guess that's just the way it is in the AIM casino.

E. Hunter: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc.

M. Dezfouli: Financial Interests, Personal, Full or part-time Employment: Oxford BioDynamics Plc.

M. Salter: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford BioDynamics Plc.

R. Powell: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc.

A. Dring: Financial Interests, Personal, Full or part-time Employment: Oxford BioDynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford BioDynamics Plc.

J. Green: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc; Financial Interests, Personal, Stocks/Shares: Oxford Biodynamics Plc.

A. Akoulitchev: Financial Interests, Personal, Full or part-time Employment: Oxford Biodynamics Plc

Ground Hog Day.......people giving their shares away so cheaply because they know the price of everything and the value of nothing here.

MMs will be very grateful.

In value terms, M&A activity decreased by 30% in Q2 2023 compared with the previous quarter’s total of $72.5bn and rose by 77% as compared to Q2 2022. Related deal volume increased by 18% in Q2 2023 versus the previous quarter and was 151% higher than in Q2 2022.

Notably, healthcare-related deals accounted for a 26% share of the global pharmaceutical industry’s M&A activity in Q2 2023, up 6% over the previous quarter.

FWIW

M&A in pharmaceutical increased in Q2 2023

Brought to you by GlobalData

In the global pharmaceutical industry, there were 479 M&A deals announced in Q2 2023, worth a total value of $51bn, according to GlobalData’s Deals Database. The $10.8bn acquisition of prometheus biosciences by merck was the industry’s largest disclosed deal.

Nm

Usually inst buyers look to take min 3% stakes when they invest. Pretty difficult to get that right now for them but they will be accumulating for sure

Tricky 100% right

Volatile trading as MMs accumulate for their larger buyers.

Easy to answer that. Too many traders and many looking thinking they have missed out already. Too many focus on the share price and the chart instead of the opportunity here.

As Oscar Wilde once said

A fool is someone who knows the price of everything and the value of nothing

Not making light of pc far from it.

Please read this for some balance

https://www.sciencedirect.com/science/article/pii/S2468294220300605